TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20019606

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (n-3 FA), specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oily fish consumption as part of a balanced diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-3 FA as a treatment option
Number of subjects: 0
Study: 17181846

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg administered pre- and postoperatively
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo administered pre- and postoperatively
Number of subjects: 79
Study: 15224032

Group type: EXPERIMENTAL
Intervention: Single-level N2 disease
Number of subjects: 172

Group type: COMPARATOR
Intervention: N1 disease
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Single-level N2 metastases without concomitant N1 disease (skip metastases)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Both N1 and N2 metastases
Number of subjects: 172

Group type: COMPARATOR
Intervention: Left upper lobe tumors with N1 disease
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Left upper lobe tumors with single-level N2 disease
Number of subjects: 172
Study: 11772245

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress management strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary modification (addition of dietary fibre)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychopharmacological agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative therapies (homeopathy, acupuncture, special diets, herbal medication, psychological treatments, hypnotherapy)
Number of subjects: 0
Study: 9498441

Group type: EXPERIMENTAL
Intervention: Baseline plasma HIV RNA levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Each 10-fold lower HIV RNA concentration at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Each 10-fold decrease in HIV RNA between baseline and week 8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate analyses of baseline values or changes in infectious HIV titer or ICD p24 antigen concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma HIV-1 RNA
Number of subjects: 0
Study: 7974334

Group type: EXPERIMENTAL
Intervention: Weight adjusted dose of Fragmin (100 IU/kg) subcutaneously twice a day for 10 days (group A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Dosage based on anti factor Xa assay to obtain a target concentration of 0.5 to 1 IU/ml (group B)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 122
Study: 2690622

Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg given twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbenicillin 764 mg given every six hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 0
Study: 790112

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31527572

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31096266

Group type: EXPERIMENTAL
Intervention: Oxytocin (48 IU/day)
Number of subjects: 124
Study: 28654019

Group type: EXPERIMENTAL
Intervention: Cow's skim milk fermented with Lactobacillus paracasei CBA L74 (group A)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (maltodextrins, group B)
Number of subjects: 126
Study: 24916134

Group type: COMPARATOR
Intervention: Albuterol (A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (M)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of magnesium sulfate and albuterol (M + A)
Number of subjects: 84
Study: 23454551

Group type: EXPERIMENTAL
Intervention: CBT (Cognitive and Behavioural Therapy) for 6 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 68
Study: 21300930

Group type: EXPERIMENTAL
Intervention: AC→T (sequential doxorubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAC (concurrent doxorubicin, cyclophosphamide, and docetaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AT (doxorubicin and tamoxifen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC→T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment arm, time point, age, and tamoxifen use
Number of subjects: 0
Study: 19011957

Group type: EXPERIMENTAL
Intervention: Using clinical irrelevance criteria for covariate selection
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Dividing elimination into renal and non-renal parts
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: First-order (FO) and first-order conditional estimation (FOCE) methods
Number of subjects: 1445
Study: 16569562

Group type: EXPERIMENTAL
Intervention: FilterWire EX
Number of subjects: 651

Group type: COMPARATOR
Intervention: GuardWire
Number of subjects: 651
Study: 12913194

Group type: EXPERIMENTAL
Intervention: Sunlight exposure for 12 months
Number of subjects: 258

Group type: COMPARATOR
Intervention: Sunlight deprivation (control group)
Number of subjects: 258
Study: 10859037

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 236
Study: 9101627

Group type: EXPERIMENTAL
Intervention: Patient-centred, self-directive intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 110
Study: 8461269

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2946604

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (Diane, 2 mg)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (Androcur, 100 mg)
Number of subjects: 158
Study: 31169293

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted inactivated A(H7N9) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted inactivated A(H7N9) vaccine
Number of subjects: 0
Study: 28796885

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Imiquimod (IMIQ)
Number of subjects: 35
Study: 26903255

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention (CBP) program
Number of subjects: 310

Group type: COMPARATOR
Intervention: Usual community care (UC)
Number of subjects: 310
Study: 24103087

Group type: EXPERIMENTAL
Intervention: Take-home naloxone (THN) training
Number of subjects: 187

Group type: COMPARATOR
Intervention: Basic information on opioid overdose management (control)
Number of subjects: 187
Study: 23101741

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Community intervention
Number of subjects: 48
Study: 19602720

Group type: EXPERIMENTAL
Intervention: Xuezhikang (n = 772)
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Placebo (n = 758)
Number of subjects: 1530
Study: 17764597

Group type: EXPERIMENTAL
Intervention: Heat-inactivated lactic acid-fermented oat gruel with added viable, lyophilized Lactobacillus plantarum 299v
Number of subjects: 18

Group type: COMPARATOR
Intervention: Heat-inactivated lactic acid-fermented oat gruel without added viable, lyophilized Lactobacillus plantarum 299v
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 18
Study: 15843914

Group type: EXPERIMENTAL
Intervention: Pramlintide (120 microg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12197890

Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: combined serological testing
Number of subjects: 23
Study: 9807036

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7880225

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 900
Study: 2509103

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK arm)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Streptokinase and Nitroglycerin (SK-NTG arm)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Nitroglycerin alone (NTG arm)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control (conventional therapy without acute catheterization)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK arms)
Number of subjects: 393
Study: 788451

Group type: EXPERIMENTAL
Intervention: Isoxsuprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 30353600

Group type: EXPERIMENTAL
Intervention: Accelerated transition from oncological treatment to home-based specialized palliative care (SPC) and dyadic psychological support
Number of subjects: 258

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 258
Study: 27809351

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day) plus sertraline (200 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo plus sertraline (200 mg/day)
Number of subjects: 66
Study: 25268289

Group type: EXPERIMENTAL
Intervention: Dynamic squats without vibration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Static squats without vibration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dynamic squats with 30‐Hz WBV
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Static squats with 30‐Hz WBV
Number of subjects: 21
Study: 24045883

Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg/d)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 22267349

Group type: EXPERIMENTAL
Intervention: Mentored doctors
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-mentored doctors
Number of subjects: 64
Study: 19863279

Group type: EXPERIMENTAL
Intervention: Adenosine inhalation challenge
Number of subjects: 57

Group type: COMPARATOR
Intervention: Methacholine inhalation challenge
Number of subjects: 57
Study: 17302253

Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg once daily for 48 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg once daily for 48 weeks)
Number of subjects: 40
Study: 14966092

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) plus carboplatin AUC6
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m(2) plus carboplatin AUC6
Number of subjects: 502
Study: 11306394

Group type: EXPERIMENTAL
Intervention: Dilatation followed by a self-catheterization regimen
Number of subjects: 753

Group type: COMPARATOR
Intervention: Control group (men who did not develop anastomotic strictures)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Stricture group (men who developed anastomotic strictures)
Number of subjects: 753
Study: 9135312

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 0.5 ml (25 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 0.5 ml (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 0.5% 2 ml
Number of subjects: 60
Study: 14502840

Group type: EXPERIMENTAL
Intervention: Low folate status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidemiological studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potential inhibition of precursor lesions
Number of subjects: 0
Study: 2444308

Group type: EXPERIMENTAL
Intervention: Bromocriptine 7.5 mg daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31482319

Group type: EXPERIMENTAL
Intervention: Fab antivenom (FabAV)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 29781289

Group type: EXPERIMENTAL
Intervention: Direct Anterior (DA) approach
Number of subjects: 78

Group type: COMPARATOR
Intervention: Direct Lateral (DL) approach
Number of subjects: 78
Study: 27607187

Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: darifenacin 7.5 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 26325083

Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 100
Study: 23803012

Group type: EXPERIMENTAL
Intervention: Navigators met with intervention patients to provide transplant information and assistance.
Number of subjects: 167

Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 167
Study: 20107867

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 0.5 ml preservative-free 1% intracameral lidocaine (2 drops of proxymethacaine 0.5%)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Subtenon anaesthesia with 4 ml 2% lignocaine
Number of subjects: 54
Study: 19441669

Group type: EXPERIMENTAL
Intervention: peg‐IFNalpha2a (n=18) or peg‐IFNalpha2b (n=8) plus RBV in standard doses
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study: 16025959

Group type: EXPERIMENTAL
Intervention: Modified Sanjiasan decoction (MSD), one dosage each day for three months.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Naofukang 0.8 g three times a day for three months (Control).
Number of subjects: 68
Study: 14636753

Group type: EXPERIMENTAL
Intervention: Oxandrolone 20mg per day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nutrition alone
Number of subjects: 45
Study: 10781760

Group type: COMPARATOR
Intervention: AAI pacing
Number of subjects: 21

Group type: COMPARATOR
Intervention: DDD pacing from RV apex or high septum
Number of subjects: 21

Group type: COMPARATOR
Intervention: VVI pacing from both RV sites
Number of subjects: 21

Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 21
Study: 9060320

Group type: EXPERIMENTAL
Intervention: i.v. catheter (group A)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Vacutainer venipuncture (group B)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: i.v. catheter diameter
Number of subjects: 165
Study: 1714951

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1; Bleomycin 15 mg IV day 1, and 16 mg/m2/d CI days 1 to 5; Fluorouracil 650 mg/m2/d CI days 1 to 5 (PBF)
Number of subjects: 49
Study: 6172999

Group type: EXPERIMENTAL
Intervention: Morphine (1 mg . kg‐1, iv at 100 micrograms . kg‐1 . min‐1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fentanyl (50 micrograms . kg‐1 at 5 micrograms . kg‐1 . min‐1)
Number of subjects: 15
Study: 31368756

Group type: EXPERIMENTAL
Intervention: Animated visualization intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 96
Study: 27759463

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W (80 mg every two weeks after a 160 mg starting dose)
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W (80 mg every four weeks after a 160 mg starting dose)
Number of subjects: 3866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3866

Group type: COMPARATOR
Intervention: Etanercept (50 mg bi-weekly)
Number of subjects: 3866
Study: 27167403

Group type: EXPERIMENTAL
Intervention: Right prefrontal tDCS with visuospatial WM training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Left prefrontal tDCS with visuospatial WM training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham stimulation with visuospatial WM training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Right prefrontal tDCS with spaced training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Right prefrontal tDCS
Number of subjects: 62
Study: 25060189

Group type: EXPERIMENTAL
Intervention: Community-based participatory eye health intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 22096031

Group type: EXPERIMENTAL
Intervention: High ST2 concentrations (>35 μg/L)
Number of subjects: 4426

Group type: EXPERIMENTAL
Intervention: ST2 biomarker
Number of subjects: 4426

Group type: COMPARATOR
Intervention: Ranolazine
Number of subjects: 4426
Study: 18815445

Group type: EXPERIMENTAL
Intervention: Direct-current cardioversion (DCC)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion
Number of subjects: 374

Group type: COMPARATOR
Intervention: Wait-and-watch
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Direct-current cardioversion (DCC) vs Pharmacological treatment
Number of subjects: 374
Study: 17206078

Group type: EXPERIMENTAL
Intervention: Bravo capsule
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional naso-oesophageal catheter
Number of subjects: 200
Study: 15991867

Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin A (BTX‐A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Structured rehabilitation (physiotherapy and occupational therapy three times a week for 6 months)
Number of subjects: 20
Study: 16036283

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: High levels of nicotine dependence
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Higher levels of baseline depression symptoms
Number of subjects: 1070
Study: 10229308

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 16
Study: 8560678

Group type: EXPERIMENTAL
Intervention: 200 mg daily bicalutamide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 300 mg daily bicalutamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: 450 mg bicalutamide
Number of subjects: 20
Study: 1883258

Group type: EXPERIMENTAL
Intervention: High-dose right unilateral electroconvulsive therapy (378-mC charge)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bilateral electroconvulsive therapy
Number of subjects: 38
Study: 6948949

Group type: EXPERIMENTAL
Intervention: Ultrasonic instruments
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hand instruments
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (uninstrumented)
Number of subjects: 5
Study: 30767156

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Environment (VRE) with Cognitive Behaviour Therapy (CBT); 1 session introducing CBT techniques and 4 VRE sessions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Environment (VRE) with Cognitive Behaviour Therapy (CBT)
Number of subjects: 32
Study: 30121698

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 26771522

Group type: EXPERIMENTAL
Intervention: Perindopril 5 mg/Amlodipine 5 mg (Per/Amlo group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 5 mg (Amlo group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perindopril 4 mg (Per group)
Number of subjects: 0
Study: 25088349

Group type: EXPERIMENTAL
Intervention: VascuLuminator
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (no VascuLuminator)
Number of subjects: 226
Study: 22785114

Group type: EXPERIMENTAL
Intervention: ramipril + high‐dose rapamycin (trough level 6‐8 ng/mL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ramipril + low‐dose rapamycin (trough levels 2‐4 ng/mL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: ramipril (Group A)
Number of subjects: 55
Study: 20188315

Group type: EXPERIMENTAL
Intervention: Nutritional therapy in combination with exercise training
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 199
Study: 17130281

Group type: EXPERIMENTAL
Intervention: Oxandrolone and exercise
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oxandrolone alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Placebo and exercise
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo and no exercise
Number of subjects: 51

Group type: COMPARATOR
Intervention: Exercise groups (oxandrolone and exercise, placebo and exercise)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both exercise groups
Number of subjects: 51
Study: 16355546

Group type: EXPERIMENTAL
Intervention: Dental amalgam fillings
Number of subjects: 0
Study: 11923049

Group type: EXPERIMENTAL
Intervention: Prostacyclin plus conventional therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 81
Study: 10438381

Group type: EXPERIMENTAL
Intervention: Efavirenz, 600 mg daily
Number of subjects: 10
Study: 7557702

Group type: EXPERIMENTAL
Intervention: Experimental referral form with a special area for the consultant to fill out and return to the referring family physician via the patient.
Number of subjects: 306

Group type: COMPARATOR
Intervention: Routine referral form with the patient's name, age, and reason for consultation.
Number of subjects: 306
Study: 31226959

Group type: EXPERIMENTAL
Intervention: Moderate to high intensity exercise training (8 sessions × 1.5 hours, 12 hours total)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Moderate to high intensity exercise training
Number of subjects: 16
Study: 29989171

Group type: EXPERIMENTAL
Intervention: Antioxidant (500 mg l-ascorbic acid and 450 IU dl-α-tocopherol acetate, 2 capsules/day for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (cellulose capsules of identical appearance)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Antioxidant
Number of subjects: 36
Study: 28036375

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 5831

Group type: COMPARATOR
Intervention: Control
Number of subjects: 5831

Group type: COMPARATOR
Intervention: Tonsillectomy and Control
Number of subjects: 5831
Study: 25266929

Group type: EXPERIMENTAL
Intervention: 5-week Internet-based guided self-help program based on exposure therapy with weekly student support
Number of subjects: 212

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 212
Study: 22755305

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60